| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_8e43b4ca6b41ce9f54c9a895d474c81a |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07H19-02 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-70
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-7052
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-7042
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07H19-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-7076
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07H19-16
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-12 |
| filingDate |
1991-12-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_96a141c7924550c234ddcb81e5daa4b7
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2b6836d749bd9210ad42c35713390255
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1257b0cf8a4f8e6677a5ecba3c35c870
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_82c96d39a98d7417a407a1dbcb55808d
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_43edbff63d5f18fd93fe5d8c11db2436
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_314f8baef5ad54b280a5f78d19b98b56
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b4798d43a9908e4bb724d23c49917fc3 |
| publicationDate |
1992-06-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
CA-2057432-A1 |
| titleOfInvention |
2-halogeno-oxetanocin a and phosphoric ester thereof |
| abstract |
Abstract It was found that 2-halogeno-oxetanocin A and 4'-phosphate thereof represented by the following general formula (1): (1) wherein X represents a halogen atom and R represents a hydrogen atom or a phosphoric acid residue or salts thereof exhibit a strong antiviral activity and are useful as an active ingredient of therapeutic drug for viral diseases. Further, it was also found that the compounds of this invention are characterized in that they are not inactivated by adenosine deaminase widely present in living bodies and exhibit a high residual activity. |
| priorityDate |
1990-12-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |